In a recent judgment concerning interim measures (case Ö 566-06 – Roche Aktiebolag v Orifarm AB – June 9 2006), the Swedish Supreme Court ruled it objectively necessary for a parallel trader to relabel an imported pharmaceutical product with another company's registered trade mark in order to gain effective access to the Swedish market. This exception to the exclusive rights provided by a trade mark was found justified with respect to patient safety and resistance from consumers to a product marketed under a different name to that marketed by the trade mark proprietor.
